MK-677 (Ibutamoren) Explained: Mechanism and Evidence
What the clinical trials on MK-677 (Ibutamoren) actually show on GH, IGF-1, lean mass and safety, and why we do not sell it.
TL;DR: What the data on MK-677 actually shows
What it is: MK-677 (Ibutamoren, MK-0677) is an orally active small-molecule ghrelin receptor agonist, not a peptide. It was developed by Merck and abandoned after Phase 3-stage trials.
Evidence for muscle: A 2-year RCT in 65 healthy older adults found fat-free mass rose 1.1 kg on MK-677 versus a 0.5 kg fall on placebo (P<0.001) (PMID 18981485), while an earlier trial showed it reverses diet-induced protein catabolism in healthy adults (PMID 9467534).
Evidence against blanket GH-axis optimism: In a 563-patient, 12-month Alzheimer's trial, IGF-1 rose 60-73% with zero clinical benefit on the target outcome (PMID 19015485), proof that raising GH/IGF-1 does not automatically translate into a therapeutic result.
Safety signals: Fasting glucose and insulin sensitivity worsened in the elderly RCT, and a related hip-fracture trial was stopped early after a cardiac safety signal.
Why we do not sell it: MK-677 is a non-peptide small molecule with no FDA or EMA approval for any indication, banned under WADA S2.5, and outside the research-peptide category we operate in. We point readers instead to the GHRH/GHRP peptides we do carry: sermorelin, ipamorelin and CJC-1295.
MK-677 comes up constantly in discussions about growth hormone, muscle preservation and anti-aging research, often in the same breath as the injectable GH-releasing peptides. It is a legitimate research molecule with a real, published pharmacology. It is also not a peptide, not approved anywhere, and not something peptidesdirect.io sells. This article lays out what the clinical trial literature actually demonstrates, where the muscle-relevant evidence is genuinely strong, where it is not, and what the regulatory and safety picture looks like before pointing toward the research peptides that occupy the same GH axis.
What Is MK-677 (Ibutamoren)? Mechanism of the Ghrelin-Mimetic Pathway
MK-677, also known by its development code MK-0677, is a small organic molecule, chemically distinct from a peptide, that acts as an orally active agonist at the ghrelin receptor (GHSR-1a). Ghrelin is the endogenous "hunger hormone" produced mainly in the stomach, and one of its physiological roles is to trigger pulsatile growth hormone release from the pituitary. MK-677 mimics that signal.
Mechanistically, MK-677 binds GHSR-1a in the pituitary and hypothalamus, which stimulates pulsatile GH secretion and, downstream, hepatic production of IGF-1 (insulin-like growth factor 1). This is functionally an oral alternative route to the same GH/IGF-1 axis that injectable GHRH analogues (sermorelin, CJC-1295) and GHRPs (ipamorelin) target through different receptors. Merck originally developed the compound for growth hormone deficiency, sarcopenia and recovery from hip fracture in older adults, reasoning that an oral secretagogue would be more convenient than injectable GH itself.
The dose-response relationship is well documented and repeatable. In GH-deficient adults, a 10 mg dose raised IGF-1 by roughly 52% and GH by roughly 79%, while a 50 mg dose raised IGF-1 by roughly 79% and GH by roughly 82% (PMID 9329386). This dose-dependent GH-axis activation is the pharmacological basis for everything discussed further below, both the benefits and the safety signals.
The Clinical Evidence: What Human Trials Actually Show
Three human trials anchor most of what is reliably known about MK-677 in adults.
The earliest, a 1998 study in 8 healthy adults on a 14-day calorie-restricted diet, tested whether 25 mg/day of MK-677 could counter diet-induced catabolism. Nitrogen balance, a direct marker of whether the body is breaking down or preserving protein, was restored to +0.31 +/- 0.21 g/day on MK-677 versus -1.48 +/- 0.21 g/day on placebo (P<0.01), alongside the expected rise in GH and IGF-1 (PMID 9467534). This is the mechanistic proof of concept: MK-677 can measurably slow protein breakdown during a calorie deficit.
The most cited muscle-relevant trial is a 2-year randomized controlled trial in 65 healthy adults aged 60 to 81. Over 12 months, fat-free mass rose 1.1 kg (95% CI 0.7-1.5) on MK-677 while it fell 0.5 kg (95% CI -1.1 to 0.2) on placebo (P<0.001), and GH/IGF-1 levels were restored toward youthful ranges. However, the same trial recorded no measured improvement in strength or physical function, and fasting glucose rose by about 0.3 mmol/L (5 mg/dL) with reduced insulin sensitivity (PMID 18981485). In other words, the trial shows a real body-composition effect without a matching functional benefit, and with a metabolic cost attached.
Trial design note: why the Alzheimer's trial matters here
A separate 2008 study tested MK-677 in 563 Alzheimer's patients at 25 mg/day for 12 months, specifically to see whether elevating the GH axis would slow cognitive or functional decline. Serum IGF-1 rose 60-73%, confirming the drug did exactly what it pharmacologically should, yet there was no significant difference from placebo on the trial's cognitive or functional endpoints (PMID 19015485). This is methodologically instructive: a large, well-powered, long-duration RCT can show unambiguous target engagement (IGF-1 up) with a completely flat clinical outcome. It is a useful caution against assuming that any GH/IGF-1 elevation must automatically be therapeutic for a given proposed use.
Muscle, Lean Mass and the GH/IGF-1 Axis: What the Data Supports (and Doesn't)
Pulling the three trials together gives a fairly precise picture. MK-677 reliably raises GH and IGF-1 in a dose-dependent way (PMID 9329386). It reliably reverses acute diet-induced protein catabolism over short periods (PMID 9467534). And over a full year in older adults, it reliably increases fat-free mass relative to placebo by a modest but statistically significant margin (PMID 18981485).
What it does not reliably do, based on the available randomized data, is translate into measured strength or functional gains in that same elderly cohort, and it does not guarantee that GH-axis stimulation produces a clinical benefit for every condition it might plausibly help, as the Alzheimer's trial demonstrates for a different endpoint entirely (PMID 19015485). For anyone researching lean-mass preservation, whether in the context of aging, illness, or the more recent interest in preventing lean-mass loss during GLP-1-driven weight loss, this is the honest state of the evidence: a real, measurable, but incremental body-composition signal, not a dramatic strength or performance intervention, and one that arrives with a metabolic tradeoff that has to be weighed against the benefit.
What the Community Reports
What the community reports (anecdotal, not clinical evidence)
The following is drawn from public forum discussion on MESO-Rx/thinksteroids.com, AnabolicMinds, iSARMS and UK-Muscle, plus surrounding YouTube commentary. None of this is verified clinical data, it is individual, non-representative forum posts, and it is included here only to describe what people discuss, not to validate any claim.
Perceived effects: Long-time users frequently describe MK-677 as "the next best thing to actual HGH," citing better sleep (particularly when dosed at night), faster recovery between workouts, and slow, steady body-composition change over months rather than rapid short-term results.
Dosing chatter: The most-cited range is 10-30 mg/day, with 25 mg repeatedly named the informal "sweet spot." Some describe pyramiding from 25 mg up to 37.5 mg and then 50 mg over several weeks. The general advice pattern is to start low (10-15 mg) and titrate upward.
Muscle claims are mixed and often self-skeptical. Several posters report early weight gain of 3 to 10 lbs that partly or fully reverses within days of stopping, which they attribute to water retention rather than genuine muscle. Others argue that real lean-mass gains only show up with extended use, proper diet and training, "not the compound alone."
Side effects most discussed: increased appetite described by some as "way out of control," water retention and bloating, lethargy or drowsiness, and blood-sugar issues, including one account of needing several sandwiches to recover from a hypoglycemic-type crash after a missed meal. Insulin sensitivity and prolactin/cortisol elevation are recurring worries in threads comparing MK-677 to real HGH.
Comparisons to real HGH: a common framing is MK-677 as "like HCG is to testosterone," a supportive secretagogue rather than a replacement. Some experienced posters call it clearly inferior to injectable HGH, while others defend it when paired with disciplined training and diet.
Sourcing anxiety: a strong recurring theme is fear of underdosed or fake product, with reports of "no effect even at 30 mg/day," and posters warning that unusually cheap MK-677 is a red flag and recommending only vendors offering third-party or HPLC testing.
Legality framing: community threads consistently describe MK-677 as an unscheduled gray-area substance, not FDA-approved, banned in competitive sport under WADA, legal to possess but not to sell for human consumption, a distinction posters repeat often.
A fringe claim worth flagging: one forum thread raised a concern about MK-677 promoting tumor growth, which a moderator pushed back on citing studies of reduced tumor growth. This is an unverified, contested claim circulating in community discussion, not settled science in either direction, and it is noted here only to flag it as fringe.
Overall sentiment reads as mixed-to-cautiously-positive: valued by bulking-focused users for appetite, recovery and sleep, viewed more skeptically by experienced members who question genuine muscle gains, worry about bloat/blood sugar/prolactin, and are wary of counterfeit or underdosed product in the supply chain.
Why We Do Not Sell MK-677: Legal and Regulatory Status
MK-677 is prescription-adjacent and unapproved, we do not sell it
MK-677 (Ibutamoren) has never received FDA or EMA marketing authorization for any indication. Merck discontinued its own clinical development program after Phase 3-stage trials, and the compound is not permitted as a dietary-supplement ingredient in the United States or the European Union. It is prohibited in competitive sport under WADA class S2.5 (growth hormone and releasing factors/secretagogues).
MK-677 is a non-peptide small molecule, not a peptide, and it falls entirely outside the research-peptide category peptidesdirect.io operates in. We do not sell, stock, ship or facilitate the purchase of MK-677 in any form. Nothing in this article is an instruction for sourcing, dosing toward purchase, or acquiring it, and no supplier relationship is implied.
Because MK-677 has no approved medical use and no legal supplement pathway, there is no direct, equivalent product we can point to as a substitute. What we do carry are the peptide-based tools that intervene in the same GH/IGF-1 axis through a different, injectable mechanism, and that are squarely within our research-peptide catalog.
The Research Peptides We Carry Instead: Sermorelin, Ipamorelin, CJC-1295
GHRH(1-29) analog for physiological growth hormone stimulation research
Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH(1-29) analog for GH/IGF-1 research. Research-grade lyophilized powder, specified purity >=99% (HPLC). Laboratory use only.
Growth hormone secretagogues and gonadotropins
Growth hormone axis
GHRH(1-29) analog for physiological growth hormone stimulation research
Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH(1-29) analog for GH/IGF-1 research. Research-grade lyophilized powder, specified purity >=99% (HPLC). Laboratory use only.
All three engage the GH/IGF-1 axis, but through the injectable GHRH and GHRP pathways rather than the oral ghrelin-receptor route MK-677 uses. Sermorelin is the biologically active GHRH(1-29) fragment, producing short GH pulses under continuing physiological feedback, similar in intent to MK-677's action on the pituitary but through the separate GHRH receptor rather than GHSR-1a. Ipamorelin activates the same ghrelin receptor (GHSR-1a) that MK-677 targets, but does so as an injectable peptide with a short half-life and is generally described in the literature as more receptor-selective, with comparatively lower effects on cortisol and prolactin than older GHRPs. CJC-1295 is a modified GHRH analogue, most often discussed in its DAC form for extended half-life, offering sustained GHRH receptor stimulation rather than an oral pulsatile hit.
None of these peptides is a direct substitute for MK-677's oral dosing convenience, and none of them carries MK-677's specific clinical trial base. They are simply the legal, catalog-appropriate tools available for researchers whose interest is the GH/IGF-1 axis itself, delivered via routes and receptors we can document and supply.
Questions about MK-677 availability
We do not sell or supply MK-677 (Ibutamoren) in any form, and this article does not indicate otherwise. If you have questions about the research peptides above, or about GH-axis research more broadly, contact [email protected].
Community, Further Reading and the GLP-1 Muscle-Loss Connection
Interest in the GH/IGF-1 axis and lean-mass preservation has grown alongside the rise of GLP-1 receptor agonists for weight loss, since rapid weight loss on those drugs can include a meaningful proportion of lean mass alongside fat. The mechanistic overlap is real: MK-677's best-documented muscle-relevant trial (PMID 18981485) and the GHRH/GHRP peptides above all converge on the same GH/IGF-1 signalling pathway that is relevant to preserving fat-free mass during a calorie deficit or weight-loss intervention. Readers researching that intersection may also want to review our coverage of GLP-1 agonists and lean-mass loss in the metabolic-peptides section of this blog.
FAQ
This article is for informational and educational purposes only. All mentioned peptides are intended exclusively for laboratory research and not for human consumption. We do not sell the drug this article is about. For Research Purposes Only.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.